Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma
AIM： To construct a tumor-selective replicationcompetent adenovirus （RCAd）, SG300, using a modified promoter of human telomerase reverse transcriptase （hTERT）. METHODS： The antitumor efficacy of SG300 in hepatocellular carcinoma was assessed in vitro and in vivo. In vitro cell viability by MTT assay...
Gespeichert in:
| Veröffentlicht in: | World journal of gastroenterology : WJG 2006-12, Vol.12 (47), p.7613-7620 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7620 |
|---|---|
| container_issue | 47 |
| container_start_page | 7613 |
| container_title | World journal of gastroenterology : WJG |
| container_volume | 12 |
| creator | Su, Chang-Qing Wang, Xing-Hua Chen, Jie Liu, Yong-Jing Wang, Wei-Guo Li, Lin-Fang Wu, Meng-Chao Qian, Qi-Jun |
| description | AIM： To construct a tumor-selective replicationcompetent adenovirus （RCAd）, SG300, using a modified promoter of human telomerase reverse transcriptase （hTERT）.
METHODS： The antitumor efficacy of SG300 in hepatocellular carcinoma was assessed in vitro and in vivo. In vitro cell viability by MTT assay was used to assess the tumor-selective oncolysis and safety features of SG300, and in vivo antitumor activity of SG300 was assessed in established hepatocellular carcinoma models in nude mice.
RESULTS： SG300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI. Both in Hep3B and SMMC-7721 xenograft models of hepatocellular carcinoma, SG300 had an obvious antitumor effect, resulting in a decrease in tumor volume. Its selective oncolysis to tumor cells and safety to normal cells was also superior to that of ONYX-015. Pathological examination of tumor specimens showed that SG300 replicated selectively in cancer cells and resulted in apoptosis and necrosis of cancer cells.
CONCLUSION： hTERT promoter-regulated replicative adenovirus SG300 has a better cancer-selective replication-competent ability, and can specifically kill a wide range of cancer cells with positive telomerase activity, and thus has better potential for targeting therapy of hepatocellular carcinoma. |
| doi_str_mv | 10.3748/wjg.v12.i47.7613 |
| format | Article |
| fullrecord | <record><control><sourceid>wanfang_jour_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4088042</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>23559960</cqvip_id><wanfj_id>wjg200647008</wanfj_id><sourcerecordid>wjg200647008</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-1c5b240dd238edd75d4031047cc425ec8ce3e9039ae3c69d10fb60dd17c47103</originalsourceid><addsrcrecordid>eNpVkUuP0zAUhSMEYsrAnhWyEGKXcv1InGyQRqPhIY2EhLq3XOcmdUnsju106L_HoRUPeeGFz_l87j1F8ZrCmkvRfHjcD-sjZWsr5FrWlD8pVozRtmSNgKfFigLIsuVMXhUvYtwDMM4r9ry4onI5Tbsqft64ZNM8-UC0SfZo04n4nmhHdpu77xtyCH7yCUMZcJhHnbAjv9VlxBEXAxLvjB9PyRqiO3T-aMMcic2AeVoweNDJGxzHbA_E6GCs85N-WTzr9Rjx1eW-Ljaf7ja3X8r7b5-_3t7cl0ZUkEpqqi0T0HWMN9h1suoEcApCGiNYhaYxyLEF3mrkpm47Cv22znIqjZAU-HXx8Yw9zNsJO4MuBT2qQ7CTDifltVX_vzi7U4M_KgFNA4JlwLsz4FG7XrtB7f0cXE6s8vIZQC0kQJNl7y__BP8wY0xqsnGZWjv0c1R1wyoqqzYL4Sw0wccYsP-ThYJaSl24KpeqcqlqKTVb3vw7w1_DpcUseHth7rwbHmxOudXmR29HVIxXVdvWwH8BkpSt-Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68251759</pqid></control><display><type>article</type><title>Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma</title><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Su, Chang-Qing ; Wang, Xing-Hua ; Chen, Jie ; Liu, Yong-Jing ; Wang, Wei-Guo ; Li, Lin-Fang ; Wu, Meng-Chao ; Qian, Qi-Jun</creator><creatorcontrib>Su, Chang-Qing ; Wang, Xing-Hua ; Chen, Jie ; Liu, Yong-Jing ; Wang, Wei-Guo ; Li, Lin-Fang ; Wu, Meng-Chao ; Qian, Qi-Jun</creatorcontrib><description>AIM： To construct a tumor-selective replicationcompetent adenovirus （RCAd）, SG300, using a modified promoter of human telomerase reverse transcriptase （hTERT）.
METHODS： The antitumor efficacy of SG300 in hepatocellular carcinoma was assessed in vitro and in vivo. In vitro cell viability by MTT assay was used to assess the tumor-selective oncolysis and safety features of SG300, and in vivo antitumor activity of SG300 was assessed in established hepatocellular carcinoma models in nude mice.
RESULTS： SG300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI. Both in Hep3B and SMMC-7721 xenograft models of hepatocellular carcinoma, SG300 had an obvious antitumor effect, resulting in a decrease in tumor volume. Its selective oncolysis to tumor cells and safety to normal cells was also superior to that of ONYX-015. Pathological examination of tumor specimens showed that SG300 replicated selectively in cancer cells and resulted in apoptosis and necrosis of cancer cells.
CONCLUSION： hTERT promoter-regulated replicative adenovirus SG300 has a better cancer-selective replication-competent ability, and can specifically kill a wide range of cancer cells with positive telomerase activity, and thus has better potential for targeting therapy of hepatocellular carcinoma.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v12.i47.7613</identifier><identifier>PMID: 17171789</identifier><language>eng</language><publisher>United States: Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China</publisher><subject>Adenoviridae - genetics ; Animals ; Carcinoma, Hepatocellular - pathology ; Carcinoma, Hepatocellular - therapy ; Cell Line, Tumor ; Humans ; Liver Cancer ; Liver Neoplasms - pathology ; Liver Neoplasms - therapy ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Oncolytic Virotherapy - methods ; Oncolytic Viruses - genetics ; Promoter Regions, Genetic ; Telomerase - genetics ; Xenograft Model Antitumor Assays ; 抗癌活性 ; 溶癌作用 ; 癌细胞 ; 腺病毒</subject><ispartof>World journal of gastroenterology : WJG, 2006-12, Vol.12 (47), p.7613-7620</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><rights>2006 Baishideng Publishing Group Co., Limited. All rights reserved. 2006</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-1c5b240dd238edd75d4031047cc425ec8ce3e9039ae3c69d10fb60dd17c47103</citedby><cites>FETCH-LOGICAL-c450t-1c5b240dd238edd75d4031047cc425ec8ce3e9039ae3c69d10fb60dd17c47103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088042/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088042/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17171789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Su, Chang-Qing</creatorcontrib><creatorcontrib>Wang, Xing-Hua</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Liu, Yong-Jing</creatorcontrib><creatorcontrib>Wang, Wei-Guo</creatorcontrib><creatorcontrib>Li, Lin-Fang</creatorcontrib><creatorcontrib>Wu, Meng-Chao</creatorcontrib><creatorcontrib>Qian, Qi-Jun</creatorcontrib><title>Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>AIM： To construct a tumor-selective replicationcompetent adenovirus （RCAd）, SG300, using a modified promoter of human telomerase reverse transcriptase （hTERT）.
METHODS： The antitumor efficacy of SG300 in hepatocellular carcinoma was assessed in vitro and in vivo. In vitro cell viability by MTT assay was used to assess the tumor-selective oncolysis and safety features of SG300, and in vivo antitumor activity of SG300 was assessed in established hepatocellular carcinoma models in nude mice.
RESULTS： SG300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI. Both in Hep3B and SMMC-7721 xenograft models of hepatocellular carcinoma, SG300 had an obvious antitumor effect, resulting in a decrease in tumor volume. Its selective oncolysis to tumor cells and safety to normal cells was also superior to that of ONYX-015. Pathological examination of tumor specimens showed that SG300 replicated selectively in cancer cells and resulted in apoptosis and necrosis of cancer cells.
CONCLUSION： hTERT promoter-regulated replicative adenovirus SG300 has a better cancer-selective replication-competent ability, and can specifically kill a wide range of cancer cells with positive telomerase activity, and thus has better potential for targeting therapy of hepatocellular carcinoma.</description><subject>Adenoviridae - genetics</subject><subject>Animals</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Carcinoma, Hepatocellular - therapy</subject><subject>Cell Line, Tumor</subject><subject>Humans</subject><subject>Liver Cancer</subject><subject>Liver Neoplasms - pathology</subject><subject>Liver Neoplasms - therapy</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Oncolytic Virotherapy - methods</subject><subject>Oncolytic Viruses - genetics</subject><subject>Promoter Regions, Genetic</subject><subject>Telomerase - genetics</subject><subject>Xenograft Model Antitumor Assays</subject><subject>抗癌活性</subject><subject>溶癌作用</subject><subject>癌细胞</subject><subject>腺病毒</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkUuP0zAUhSMEYsrAnhWyEGKXcv1InGyQRqPhIY2EhLq3XOcmdUnsju106L_HoRUPeeGFz_l87j1F8ZrCmkvRfHjcD-sjZWsr5FrWlD8pVozRtmSNgKfFigLIsuVMXhUvYtwDMM4r9ry4onI5Tbsqft64ZNM8-UC0SfZo04n4nmhHdpu77xtyCH7yCUMZcJhHnbAjv9VlxBEXAxLvjB9PyRqiO3T-aMMcic2AeVoweNDJGxzHbA_E6GCs85N-WTzr9Rjx1eW-Ljaf7ja3X8r7b5-_3t7cl0ZUkEpqqi0T0HWMN9h1suoEcApCGiNYhaYxyLEF3mrkpm47Cv22znIqjZAU-HXx8Yw9zNsJO4MuBT2qQ7CTDifltVX_vzi7U4M_KgFNA4JlwLsz4FG7XrtB7f0cXE6s8vIZQC0kQJNl7y__BP8wY0xqsnGZWjv0c1R1wyoqqzYL4Sw0wccYsP-ThYJaSl24KpeqcqlqKTVb3vw7w1_DpcUseHth7rwbHmxOudXmR29HVIxXVdvWwH8BkpSt-Q</recordid><startdate>20061221</startdate><enddate>20061221</enddate><creator>Su, Chang-Qing</creator><creator>Wang, Xing-Hua</creator><creator>Chen, Jie</creator><creator>Liu, Yong-Jing</creator><creator>Wang, Wei-Guo</creator><creator>Li, Lin-Fang</creator><creator>Wu, Meng-Chao</creator><creator>Qian, Qi-Jun</creator><general>Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China</general><general>Jiangsu Key Laboratory for Molecular and Medical Biotechnology, Life Science College, Nanjing Normal University, Nanjing 210097, Jiangsu Province, China%Changhai Hospital, Second Military Medical University, Shanghai 200438, China%Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China%Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China</general><general>Xinyuan Institute of Medicine and Biotechnology,College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310018, Zhejiang Province, China</general><general>Baishideng Publishing Group Co., Limited</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope><scope>5PM</scope></search><sort><creationdate>20061221</creationdate><title>Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma</title><author>Su, Chang-Qing ; Wang, Xing-Hua ; Chen, Jie ; Liu, Yong-Jing ; Wang, Wei-Guo ; Li, Lin-Fang ; Wu, Meng-Chao ; Qian, Qi-Jun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-1c5b240dd238edd75d4031047cc425ec8ce3e9039ae3c69d10fb60dd17c47103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adenoviridae - genetics</topic><topic>Animals</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Carcinoma, Hepatocellular - therapy</topic><topic>Cell Line, Tumor</topic><topic>Humans</topic><topic>Liver Cancer</topic><topic>Liver Neoplasms - pathology</topic><topic>Liver Neoplasms - therapy</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Oncolytic Virotherapy - methods</topic><topic>Oncolytic Viruses - genetics</topic><topic>Promoter Regions, Genetic</topic><topic>Telomerase - genetics</topic><topic>Xenograft Model Antitumor Assays</topic><topic>抗癌活性</topic><topic>溶癌作用</topic><topic>癌细胞</topic><topic>腺病毒</topic><toplevel>online_resources</toplevel><creatorcontrib>Su, Chang-Qing</creatorcontrib><creatorcontrib>Wang, Xing-Hua</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><creatorcontrib>Liu, Yong-Jing</creatorcontrib><creatorcontrib>Wang, Wei-Guo</creatorcontrib><creatorcontrib>Li, Lin-Fang</creatorcontrib><creatorcontrib>Wu, Meng-Chao</creatorcontrib><creatorcontrib>Qian, Qi-Jun</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Su, Chang-Qing</au><au>Wang, Xing-Hua</au><au>Chen, Jie</au><au>Liu, Yong-Jing</au><au>Wang, Wei-Guo</au><au>Li, Lin-Fang</au><au>Wu, Meng-Chao</au><au>Qian, Qi-Jun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2006-12-21</date><risdate>2006</risdate><volume>12</volume><issue>47</issue><spage>7613</spage><epage>7620</epage><pages>7613-7620</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>AIM： To construct a tumor-selective replicationcompetent adenovirus （RCAd）, SG300, using a modified promoter of human telomerase reverse transcriptase （hTERT）.
METHODS： The antitumor efficacy of SG300 in hepatocellular carcinoma was assessed in vitro and in vivo. In vitro cell viability by MTT assay was used to assess the tumor-selective oncolysis and safety features of SG300, and in vivo antitumor activity of SG300 was assessed in established hepatocellular carcinoma models in nude mice.
RESULTS： SG300 could lyse hepatocellular carcinoma cells at a low multiplicity of infection （MOI）, but could not affect growth of normal cells even at a high MOI. Both in Hep3B and SMMC-7721 xenograft models of hepatocellular carcinoma, SG300 had an obvious antitumor effect, resulting in a decrease in tumor volume. Its selective oncolysis to tumor cells and safety to normal cells was also superior to that of ONYX-015. Pathological examination of tumor specimens showed that SG300 replicated selectively in cancer cells and resulted in apoptosis and necrosis of cancer cells.
CONCLUSION： hTERT promoter-regulated replicative adenovirus SG300 has a better cancer-selective replication-competent ability, and can specifically kill a wide range of cancer cells with positive telomerase activity, and thus has better potential for targeting therapy of hepatocellular carcinoma.</abstract><cop>United States</cop><pub>Laboratory of Viral and Gene Therapy, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China</pub><pmid>17171789</pmid><doi>10.3748/wjg.v12.i47.7613</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1007-9327 |
| ispartof | World journal of gastroenterology : WJG, 2006-12, Vol.12 (47), p.7613-7620 |
| issn | 1007-9327 2219-2840 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4088042 |
| source | MEDLINE; PubMed Central; Alma/SFX Local Collection |
| subjects | Adenoviridae - genetics Animals Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - therapy Cell Line, Tumor Humans Liver Cancer Liver Neoplasms - pathology Liver Neoplasms - therapy Mice Mice, Inbred BALB C Mice, Nude Oncolytic Virotherapy - methods Oncolytic Viruses - genetics Promoter Regions, Genetic Telomerase - genetics Xenograft Model Antitumor Assays 抗癌活性 溶癌作用 癌细胞 腺病毒 |
| title | Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T03%3A59%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antitumor%20activity%20of%20an%20hTERT%20promoter-regulated%20tumor-selective%20oncolytic%20adenovirus%20in%20human%20hepatocellular%20carcinoma&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Su,%20Chang-Qing&rft.date=2006-12-21&rft.volume=12&rft.issue=47&rft.spage=7613&rft.epage=7620&rft.pages=7613-7620&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v12.i47.7613&rft_dat=%3Cwanfang_jour_pubme%3Ewjg200647008%3C/wanfang_jour_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68251759&rft_id=info:pmid/17171789&rft_cqvip_id=23559960&rft_wanfj_id=wjg200647008&rfr_iscdi=true |